Purpose To investigate the predictive value of c-erbB-2 oncoprotein expression as compared with established histopathological and cytometnc indicators of disease evolution in breast carcinoma
Introduction
Axillary lymph node status is generally accepted to be the most important prognostic factor in breast carcinoma [1] However, the heterogeneous clinical outcome of patients at the same stage of the disease led the investigators to search for additional predictive markers that might improve the individual treatment [2] [3] [4] HER-2/neu (also known as c-erbB-2 or ERBB2) is a gene located on chromosome 17q21 that encodes a 185 kD transmembrane protein with tyrosine kinase activity [5] It seems to play an important role in the development and progression of human cancer, through its biological activity as a growth factor receptor and its involvement in cell differentiation, adhesion and motility [6] [7] [8] .
c-erbB-2 oncoprotein overexpression has been found in 10%-30% of all invasive breast cancers, and in most cases of intraductal comedocarcinoma [3, 9] . Slamon et al. [10] first showed the correlation between HER-2/neu amplification and poor prognosis of breast carcinoma, and this was supported by subsequent studies in mainly patients with axillary nodal involvement [11] [12] [13] [14] [15] [16] [17] Conflicting results have been reported in node-negative disease [11] [12] [13] [14] 16] , although a recent large multicenter prospective study has demonstrated a higher risk of disease recurrence for patients expressing HER-2/neu [18] . At present, growing interest is focused on the oncogene, since several studies have reported the association of HER-2/neu amplification with resistance to endocrine and/or chemotherapy [16, [19] [20] [21] , suggesting its putative role as predictor of adjuvant treatment response as well as potential target for antibody-based therapies [7, 22] ,
The aims of our study were: (1) to correlate c-erbB-2 expression with histopathological and cytometnc characteristics commonly related to disease prognosis, in a series of 306 breast cancer patients, (2) to analyse its prognostic significance in relation to clinical outcome, as measured by the disease-free survival (DFS) and the overall survival (OS); (3) to determine by multivanate analysis the clinical impact of c-erbB-2 expression, either as an independent parameter or in combination with other markers; and (4) to identify subsets of patients with unfavourable prognosis after prognostic stratification based on axillary lymph node status and estrogenreceptor expression
Patients and methods

Clinicopathological data
The study involved 306 women with operable invasive primary breast carcinoma, diagnosed and treated at the Instituto Portugues de Oncologia -Lisbon Centre, between October 1990 and December 1996 Elegibility criteria for patients included (1) the lack of any therapy submission prior to surgery, (2) the availability of frozen samples for flow cytometry, and (3) the access to accurate follow-up information The mean age of the patients was 58 5 years (range 23-88 years) Histological material was analysed using haematoxylin and eosin staining The histological type and tumour staging were evaluated according to the TNM-UICC system [23] . The whole series encompassed 273 invasive ductal carcinomas not otherwise specified-NOS (89 2%) and 33 carcinomas of other histological types (108%) II lobular, II mucinous, 4 papillary. 2 apocnne, 2 tubular, 2 medullary, and 1 metaplastic Lymph node sampling was carried out on the basis of histological analysis [23], the patients being categorised into two groups pN 0 (without nodal involvement 173 cases) and pN| (with nodal involvement 133 cases) Tumour differentiation was assessed using the Nottingham grading criteria [24] 86 carcinomas (28 1%) were classified as Gl (well differentiated), 138 (45 1%) as G2 (moderately differentiated) and 82 (26 8%) as G3 (poorly differentiated) Two hundred seventy-eight patients (90 8%) were treated by modified radical mastectomy, and twenty-eight (9 2%) received conservative treatment (tumorectomy or quadrantectomy) All the patients underwent axillary dissection In general, the adjuvant therapy guidelines recommended at our institution were followed (I) adjuvant chemotherapy was administered to all node-positive premenopausal patients and hormone receptor negative postmenopausal patients, as well as the node-negative patients showing high risk characteristics of tumour recurrence (tumour size >2 cm, poor differentiation, and lack of hormone receptors expression), (2) endocrine treatment with tamoxifen was given to all hormone receptors positive postmenopausal patients, (3) local radiotherapy (Rx) was given postoperatively to the patients treated with conservative breast surgery, while the node-positive patients received radiotherapy to the axillary region In brief, 84 patients received chemotherapy, 46 hormonotherapy, 33 chemotherapy + Rx + hormonotherapy, 84 chemotherapy + Rx, 43 chemotherapy + hormonotherapy, and 9 Rx + hormonotherapy Seven patients received no adjuvant therapy The patients were followed up by routine clinical examination every 4 months for the first year, at least every 6 months for the next 4 years and at intervals of 12 months thereafter Information on survival (DFS and OS) was obtained directly from clinical charts and through the epidemiological registry service at our institution (ROR-Sul) The study end points were the disease-free survival (the interval between surgical resection and the appearance of the first recurrence or metastasis) and the overall survival (the time elapsed from surgery to the most recent clinical observation or death) The median follow-up period was 396 months (range 3-84 months) At the end of the follow-up time, 254 patients (83%) were alive without evidence of disease. 17 (5 6%) were alive with disease, and 34 (II 1%) had died of their disease One patient who died from an unrelated cause was censored from the survival analysis study lmmunohistochemistry c-erhB-2 expression c-erbB-2 immunostaining was performed on 2-3 urn thick sections obtained from paraffin-embedded tissue using the streptavidin-biotin ) was used as chromogen for eight minutes, followed by Mayer's haemaloxylin counterstaining Appropriate cases of breast comedocarcinoma with known reactivity for the antibody were used as positive control Negative control reactions were performed by omitting the primary antibody Breast carcinoma cells that showed any intensity membrane staining were considered to be positive Cytoplasmic staining, in the absence of membrane staining reinforcement, was disregarded [17] A diffuse cell membrane immunoreactivity throughout the slide was characteristically found in most c-erbB-2 positive tumours ( Figure I) 
Hormone receptors expression
Estrogen receptor (ER) and progesterone receptor (PgR) assays were performed as previously reported [26] , using the streptavidin-biotin complex peroxidase technique, with primary monoclonal antibodies anti-estrogen receptor and anti-progesterone receptor (NCL-estrogen receptor-6Fll and NCL-PGR, respectively, Novocastra Laboratories) Pretreatment procedures included endogeneous peroxidase blocking with hydrogen peroxidase, and antigen retrieval using a pressure cooking and citrate buffer, pH 6 [27] The results were recorded as the percentage of positively stained target cells, positive samples being defined as those showing more than 10% stained tumour cell nuclei DNA flow cytometry DNA flow cytometnc analysis was performed on representative fresh/ frozen unfixed samples taken from surgical resected tumour tissue, as described in detail previously [26] After obtaining a monodispersed cell yield by using mechanical disaggregation, specimens were stained with propidium iodide solution (Sigma), 50 ug/ml inTns-MgCl2 buffer, for one hour in the dark at 4°C, treated with Ribonuclease (Sigma) and Nonidet P40 (Sigma), and then filtered through a 55 urn nylon mesh The stained nuclei were analysed on an Epics Profile II flow 9 5) 21 (126) 22 (17 1) 3( 3 7) 22(16 5) 34 (20 4) 9 (7 0) 34 (20 4) 6 (5 4) 28(23 7) 24 (11 0) 19 (24 7) 21 (11 7 The histograms were lilted to a model that applies systematic background sliced nuclei debris subtraction and aggregates correction, in accordance to previous reproducibihty studies [29] The mean coefficient of variation of tumour Go-G| peaks was 4 2% (range 2 4%-7 8%) Mixed non-malignant cells from the same sample analysed, namely lymphocytes, fibroblasts, and normal epithelial cells, were used as the diploid reference population DNA ploidy status was defined according to guidelines proposed at the DNA Cytometry Consensus Conference [30], tumours with only one cell population being considered as DNA diploid and those showing two or more cell populations as DNA aneuploid S-phase fraction (SPF), as a measure of tumour prohferative activity, was calculated from the DNA histogram using the zero-order polynomial model [28] The SPF median value of 6 1% was used as cut-off point, and tumours were accordingly classified into low prohferative (<6 1%) and high prohferative (5= 6 1%) SPF could not be assessed in 70 cases (22 9%), due to high levels of background debris and/or cell populations overlapping on DNA histogram
Statistical analysis
The correlation of c-erbB-2 expression with other prognostic factors was assessed by the chi-square test and the Fisher's exact test (when the expected frequencies were less than 5) The survival rates for breast cancer patients were determined using the Kaplan-Meier method [31], the differences between survival curves being analysed by means of the log-rank test [32] The independent effect of each variable on recurrence and survival was evaluated by multivanate analysis, using the Cox proportional hazards regression model [33] Estimates of the relative risk and 95% confidence intervals were calculated from the model, the statistical significance being determined by the Wald test P-values less than 0 05 were considered to be significant Results c-erbB-2 assessment failed in II cases, due to lack of appropriate tissue sample. Forty-three (14 6%) of the remaining two hundred ninety-five tumours presented c-erbB-2 lmmunoreactivity, forty-two of them being classified as ductal invasive carcinomas-NOS. Only 1 of 33 (3%) non-NOS ductal carcinomas (an apocrine carcinoma) showed oncoprotein overexpression. The correlation of c-erbB-2 expression with histopathological and cytometnc parameters commonly related to disease prognosis is shown in Table 1 . High tumour grade, DNA aneuploidy, increased prohferative activity and lack of estrogen receptors were statistically significantly associated with c-erbB-2 positivity. There was a trend, without statistical significance, towards progesterone receptors negativity, but no correlation with either tumour size or with nodal status was verified.
Patients with c-erbB-2 positive tumours had a significantly worse prognosis as compared to those not overexpressing the oncoprotein (three-year DFS and OS 68.8% vs. 85.9% and 86% vs. 92 7%, respectively) ( Figure 2 ). Univariate analysis showed that c-erbB-2 expression, as well as tumour size, nodal involvement. Abbreviations RR relative risk CI -confidence interval, P + S+c -Ploidy plu.i S-phase fraction plus c-erbB-2 expression /•-value Wald lesi " Reference category histological grade, DNA ploidy, SPF and hormone receptors had marked influence in relation to DFS, while c-erbB-2, together with nodal status, cytometnc parameters and ER and PgR content were significantly correlated to OS (Table 2) . When tumours were subgrouped according to three variables -ploidy, SPF and c-erbB-2 (P + S + c) -the combined category showed a statistically significant correlation with disease outcome (Figure 3 ). Group 1 (diploid, low proliferative, c-erbB-2 negative tumours, n -100) exhibited a more favourable clinical outcome (three-year DFS and OS. 95.9% and 97 9%, respectively) as compared to group 3 (aneuploid, high proliferative, c-erbB-2 positive tumours, n -25) (three-year DFS and OS 67 9% and 85.4%, respectively). Group 2 (all the other tumours; n = 105) demonstrated an intermediate prognosis (three-year DFS and OS: 79 5% and 897%, respectively). In multivariate analysis, c-erbB-2 per se, together with tumour size, histological grade and hormone receptors lost their value as independent predictors of recurrence and overall survival, contrasting to nodal status (P < 0.001) and P + S + c subgrouping (group 2. P -0.002, group 3: P = 0 001) in relation to DFS, and nodal status (P = 0.001) and DNA ploidy {P -0.006) in relation to OS (Table 3) . The prognostic significance of c-erbB-2 expression and other histopathological and cytometnc characteristics according to nodal status (pN 0 vs. pN|) is shown in Tables 4 and 5 , respectively. No prognostic indicators were found in node-negative breast cancer patients, but in the node-positive group, with the exception of tumour size (DFS and OS) and histological grade (OS), all parameters evaluated showed a statistically significant correlation with clinical outcome In this subset, c-erbB-2 Abbreviations DFS -disease-free survival, OS -overall survival, n -number of cases, SPF -S-phase fraction. P + S + c -ploidy plus SPF plus C-erbB-2 /'-value log-rank test revealed a trend that did not reach statistical significance (DFS. P = 0.068, OS. P = 0.086) (Figure 4 ) We also investigated the prognostic value of c-erbB-2 expression by estrogen receptor status for both DFS and OS. No predictive impact was verified in patients with ER negative tumours (DFS: P = 0 632, OS P = 0.948). Conversely, c-erbB-2 overexpression showed a statistically significant correlation with worse clinical outcome in ER positive patients (DFS: P -0 015, OS: P = 0.004) ( Figure 5 ), interestingly those receiving endocrine therapy with tamoxifen ER positive (ER+) breast cancer patients that concomitantly presented c-erbB-2 positive tumours exhibited a three-year poorer DFS and OS (67.2% and 89.5%, respectively) as compared to those that did not express the oncoprotein (87.8% and 94.3%), with a relative risk of 2.72 (1.17-6.30; P = 0 020) and 3.69 (1.41-9.64; P -0.008) for DFS and OS, respectively The relationship between c-erbB-2 expression and tumour proliferative activity, as assessed by SPF, according to estrogen receptor status is illustrated in Tables 6 and 7 . c-erbB-2 overexpression was significantly associated with high SPF in ER positive (ER+) breast carcinomas (P < 0.001), but in ER negative tumours no correlation was found (P -1.000).
Discussion
Several studies have reported the clinical utility of HER-2/neu amplification and/or its oncoprotein overexpression as prognostic indicators in breast carcinoma [14] [15] [16] 21] . This is in part corroborated by our results, since c-erbB-2 overexpression was significantly associated with early recurrence and shortened survival (Figure 2) . However, when compared with other factors in multivanate analysis it lost prognostic value, as occurred with tumour size, histological grade and hormone receptors expression. The combined evaluation of c-erbB-2 with the cytometric parameters ploidy and S-phase fraction defines a new category (P + S + c) that showed independent prognostic significance in relation to disease recurrence. The finding highlights the clinical utility of these biomarkers as part of a more accurate prognostic index [34] . Our results (Table 3 ) also confirmed the critical relevance of nodal status and DNA ploidy as independent parameters in predicting disease evolution [26, 35] The incidence of c-erbB-2 overexpression in our study was 14 6%, which seems lower than that usually reported. However, similar or even lower values have been found Table 4 P-value log-rank test in recent studies [17, 36, 37] To optimise the lmmunohistochemistry analyses and to avoid the presence of false negative results, we have previously tested an assay system to validate the use of an antibody directed against the internal domain of the c-erbB-2 protein (A 485 Dako), which in general is preserved following formalinfixation and paraffin processing [38] The relatively low percentage of c-erbB-2 overexpression found in breast carcinoma [12, 16, 19, 39] points to the need of large studies with longer follow-up periods, in order to demonstrate significant correlations between the parameter and clinical outcome [12, 14] . In this sense, the results of our short-term follow-up study should be interpreted as preliminary
In our series, only 1 of 33 (3%) non-NOS ductal carcinomas showed c-erbB-2 immunoreactivity, which is consistent with the relative rarity of c-erbB-2 positive breast cancer other than common ductal invasive types [17, 21] . c-erbB-2 overexpression was significantly correlated with aggressive tumour phenotypic characteristics, namely poor differentiation [12] [13] [14] [15] [16] , DNA aneuploidy [9, 14] , high proliferative activity [14, 15] and lack of hormone receptors activity [14-16, 19, 39] . The close association of c-erbB-2 with parameters that reflect genomic instability, suggests that the presence of the oncoprotein may provide a proliferative growth advantage to neoplastic tumour cells [13] Kallioniemi et al [14] , in the retrospective study of 319 patients with a median 9 8-year follow-up, as well as Ciocca et al [39] in a large series of 1103 primary breast carcinomas, have shown similar findings. In agreement with previous studies [12, [40] [41] [42] , no significant association between the oncoprotein expression and disease stage, based on tumour size and nodal status, was observed.
c-erbB-2 overexpression is commonly associated with poor prognosis in mainly node-positive cases [10] [11] [12] [13] [14] , the relationship being less frequently reported in nodenegative disease [14, 18] . We found a higher, although not statistically significant, prognostic impact of the marker in the former group (Table 5) . Rosen et al.
[43] studied a series of 440 node-negative breast cancer patients with a median 10-year follow-up, and concluded that HER-2/neu immunohistochemical expression is not prognostically significant. As suggested by Sjogren et al.
[34], the finding could reflect the stronger damaged cell effect of the oncoprotein in the node-positive group, leading to a more malignant tumour phenotype. On the other hand, it could be explained in statistical terms, by the lower number of events and the less frequent use of effective adjuvant therapies in node-negative patients [16, 44] . In our series, the heterogeneous therapeutic regimens used and the scarce presence of events within each categorised subgroup made the separate analysis of patients by nodal status difficult (e.g only 9 patients died and 11 had recurrences in the node-negative group), and precluded the inclusion of therapy as a variable to be tested in multivariate analyses Taking into account these methodological limitations and, therefore, regarding the corresponding results with caution, we found no prognostic indicators in node-negative patients. Conversely, in node-positive group, cytometric parameters, P + S + c tumour subgrouping and hormone receptors seem to provide significant information in relation to survival A major finding of our study is the worse clinical outcome of patients with ER-positive/c-erbB-2-positive tumours, with a relative risk of 2.72 and 3.69 for recurrence and survival, respectively. This seems to support the hypothesis that oncoprotein overexpression is associated with resistance to tamoxifen therapy Other investigators also proved such correlation [11, 19, 20, 34, 40] . Allred et al [21] studied 613 node-negative patients with long-term follow-up, and identified a subset of small estrogen receptor positive/c-erbB-2 positive tumours with poor prognosis Carlomagno et al [19] also showed, in a series of 145 early-stage breast cancer patients, that c-erbB-2 overexpression, although not being an independent prognostic factor, affects the efficacy of adjuvant therapy with tamoxifen. The clinical importance of the finding stems from the fact that, in this subset, patients without c-erbB-2 overexpression seem to respond better to hormonotherapy, whereas those with c-erbB-2 positive tumours may not benefit from its clinical use. The experimental studies of Benz et al [45] and Liu et al [46] on breast cancer cell lines, also pointed to the potential role of c-erbB-2 in resistance to endocrine therapy. Borg et al [47] have explained the more aggressive behaviour of ER-positive (ER+) tumours overexpressing the oncoprotein by the correlation between c-erbB-2 and high proliferation rates Our data support this interpretation, since c-erbB-2 expression significantly correlated with SPF in ER positive (ER+) breast carcinomas (Table 6 ), in contrast to ER negative tumours (Table 7) . It should be noted, however, that the latter group was relatively small (n = 52), and thus the conclusions may be affected by sampling error. Despite the positive results, some retrospective clinical studies have found no correlation between oncoprotein expression and resistance to endocrine therapy [48, 49] .
It is interesting to note that our data strongly suggest that the clinical implications of c-erbB-2 overexpression in breast carcinoma may be more predictive than prognostic, especially where the patient's response to adjuvant therapies is concerned. The association between c-erbB-2 expression and poor disease outcome seems to u Chi-square test Table 7 Correlation between c-erbB-2 expression and S-phase fraction in estrogen receptor negative (ER-) breast cancer patients In conclusion, our data show that c-erbB-2 alone provides limited prognostic information in breast carcinoma, but may have clinical utility, and predictive therapeutic implications, as an indicator of poor prognosis in the subgroup of patients with ER positive (ER+) tumours In addition, when analysed in conjunction with flow cytometnc ploidy and SPF, the combined category shows independent prognostic value in relation to disease recurrence. 
